If you are moderately to severely immunocompromised, you are at increased risk of severe COVID-19 illness and death. Additionally, your immune response to vaccination may not be as strong as in people who are not immunocompromised, so additional vaccine doses are needed. Even after receiving all recommended vaccines, LLS encourages blood cancer patients to take additional precautions, like wearing a mask and social distancing.

As of September 2, 2022 there are two types of booster doses available. Updated (bivalent) boosters add Omicron-specific protection along with protection against the original COVID-19 strain. The bivalent vaccine is recommended for everyone 12 years and older regardless of their immune status. The original monovalent booster vaccines is still recommended for certain children younger than age 12 years until the updated booster becomes available for them.

### Moderna (Spikevax)

**Ages 6 months – 11 years**

- **Primary Dose 1**
- Wait 4 weeks
- **Primary Dose 2**
- **Additional primary dose for immunocompromised patients**
  - Wait at least 4 weeks
- **Primary Dose 3**

A booster dose is not recommended at this time.

**Ages 12 years and older**

- **Primary Dose 1**
- Wait 4 weeks
- **Primary Dose 2**
- **Additional primary dose for immunocompromised patients**
  - Wait at least 4 weeks
- **Primary Dose 3**
  - Wait 2 months after third primary dose or last monovalent booster

**Bivalent Booster**

Note: For 18+ can be either Pfizer-BioNTech or Moderna; for 12-17 can only be Pfizer-BioNTech

---

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at [www.LLS.org](http://www.LLS.org).
### COVID-19 Vaccination Schedule for Moderately to Severely Immunocompromised Patients

<table>
<thead>
<tr>
<th>Ages 6 months – 4 years</th>
<th>Ages 5 – 11 years</th>
<th>Ages 12 years and older</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Dose 1</strong></td>
<td><strong>Primary Dose 1</strong></td>
<td><strong>Primary Dose 1</strong></td>
</tr>
<tr>
<td>Wait 3 weeks</td>
<td>Wait 3 weeks</td>
<td>Wait 3 weeks</td>
</tr>
<tr>
<td><strong>Primary Dose 2</strong></td>
<td><strong>Primary Dose 2</strong></td>
<td><strong>Primary Dose 2</strong></td>
</tr>
<tr>
<td>Wait at least 8 weeks</td>
<td>Wait at least 8 weeks</td>
<td>Wait at least 4 weeks</td>
</tr>
<tr>
<td><strong>Primary Dose 3</strong></td>
<td><strong>Primary Dose 3</strong></td>
<td><strong>Primary Dose 3</strong></td>
</tr>
<tr>
<td>Wait at least 3 months</td>
<td></td>
<td>Wait at least 2 months after third primary dose or last monovalent booster</td>
</tr>
</tbody>
</table>

**Additional primary dose for immunocompromised patients**

A booster dose is not recommended at this time.

**Monovalent Booster**
Note: Only monovalent Pfizer-BioNTech booster is approved for this age group.

**Bivalent Booster**
Note: For 18+ can be either Pfizer-BioNTech or Moderna; for 12-17 can only be Pfizer-BioNTech

---

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Find out more at [www.LLS.org](http://www.LLS.org).

As of September 8, 2022 | page 2 of 3
COVID-19 Vaccination Schedule
for Moderately to Severely Immunocompromised Patients

**Novavax**

Ages 12 years and older

<table>
<thead>
<tr>
<th>Process</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Dose 1</td>
<td>Wait 3 weeks</td>
</tr>
<tr>
<td>Primary Dose 2</td>
<td>Wait at least 2 months after second primary dose</td>
</tr>
<tr>
<td>Bivalent Booster</td>
<td>Note: For 18+ can be either Pfizer-BioNTech or Moderna; for 12-17 can only be Pfizer-BioNTech</td>
</tr>
</tbody>
</table>

Get vaccinated as recommended even if you had COVID-19

Keep practicing social distancing and masking

Talk to your healthcare team if unsure of your risk

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at [www.LLS.org](http://www.LLS.org).